A little over a year ago, I wrote an article expressing my opinion about the drug donanemab; at that time it was being promoted as a “BREAKTHROUGH” in Alzheimer’s research, but the scientific data did not support such expectations. Today, Lecanemab (Leqembi) has been approved by the European Commission to treat early‑stage Alzheimer’s disease. However, … Continue reading Lecanemab and Beyond: Shifting from Pharma Hype to Real Neuroprotective Care →